NCT04915183 2026-03-09
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
National Institutes of Health Clinical Center (CC)
Sound Pharmaceuticals, Incorporated
FDA Office of Orphan Products Development